Figure 1. p53^R175H expression leads to c-Met activation in an HGF-independent manner. (A) Inhibition with AG11478 EGFR tyrosine kinase inhibitor (1uM) for 120 min. (B and C) Inhibition with anti-HGF antibody or the PHA665752 phospho-Met inhibitor. (D) Activation of phospho-Met in EPC2-hTERT-EGFR-p53^R175H can be attenuated by using keratinocyte basal medium (KBM) or using keratinocyte serum free medium (KSFM) without BPE (bovine pituitary extract) and EGFR supplements. (E) Treatment of cells with condition media from EPC2-hTERT-EGFR-p53^R175H cells does not activate phospho-Met in EPC2-hTERT-neo-puro or EPC2-hTERT-EGFR-puro.